Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MedFirst Healthcare Services, Inc. (4175.TWO)
Taoyuan City, TW
MedFirst Healthcare Services, Inc., established in 1990 and headquartered in Taoyuan City, Taiwan, is a prominent distributor of medical supplies throughout Taiwan and China. The company's diverse product range includes diabetes management items, respiratory treatment solutions, incontinence and wound care products, various medical devices, ostomy support systems, and pain relief remedies. It also provides nutritional supplements, rehabilitation aids, and products for homecare, childcare, and maternal health. Beyond medical necessities, MedFirst offers general wellness and lifestyle goods, such as beauty products, cosmetics, and health-conscious food and beverages. In addition to its sales through retail outlets and an online platform, the firm serves as a contractor for hospital medical supply departments, acts as an agent for international medical brands, and engages in the trade of water ionizers. Its comprehensive services extend to laundry provisions and prescription drug dispensing. Furthermore, MedFirst is involved in the management of shopping complexes located within hospitals.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.93% | -2.21% | -4.33% | -8.46% | -6.85% | -10.62% | -20.42% | -53.52% | -8.62% | -25.52% | +34.28% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+3.6% Q1'26: -0.7% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%+123.0% ★ Q1'26: -58.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+1.6% Q1'26: +20.1% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+2.6% Q1'26: +1.7% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+3.8% Q1'26: +2.4% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%-0.2% ★ Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×17.00× Q1'26: 27.37× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.87B
est.
|
4.19B
est.
|
4.38B
est.
|
4.58B
est.
|
5.30B
est: 4.99B (+6.3%)
|
5.93B
est: 5.80B (+2.2%)
|
6.54B
est: 6.38B (+2.5%)
|
7.45B
est: 7.45B (+0.0%)
|
7.73B
est: 8.04B (-3.8%)
|
8.01B
est: 7.94B (+0.9%)
|
| EBITDA |
452.42M
est.
|
489.78M
est.
|
511.64M
est.
|
535.37M
est.
|
261.62M
est: 583.53M (-55.2%)
|
666.89M
est: 677.75M (-1.6%)
|
686.17M
est: 745.78M (-8.0%)
|
873.32M
est: 870.39M (+0.3%)
|
924.25M
est: 801.13M (+15.4%)
|
210.88M
est: 791.06M (-73.3%)
|
| EBIT |
89.25M
est.
|
96.62M
est.
|
100.93M
est.
|
105.61M
est.
|
174.16M
est: 115.11M (+51.3%)
|
155.31M
est: 133.69M (+16.2%)
|
96.36M
est: 147.11M (-34.5%)
|
128.32M
est: 171.70M (-25.3%)
|
154.33M
est: 236.71M (-34.8%)
|
210.88M
est: 233.73M (-9.8%)
|
| Net Income |
167.60M
est.
|
175.27M
est.
|
114.08M
est.
|
125.22M
est.
|
141.03M
est: 141.08M (0.0%)
|
109.85M
est: 186.57M (-41.1%)
|
67.93M
est: 163.96M (-58.6%)
|
46.80M
est: 79.24M (-40.9%)
|
69.82M
est: 105.69M (-33.9%)
|
155.57M
est: 90.89M (+71.2%)
|
| SGA |
1.10B
est.
|
1.19B
est.
|
1.24B
est.
|
1.30B
est.
|
1.47B
est: 1.41B (+3.9%)
|
1.67B
est: 1.64B (+1.8%)
|
1.81B
est: 1.81B (+0.4%)
|
2.16B
est: 2.11B (+2.6%)
|
2.26B
est: 1.82B (+23.9%)
|
—
est: 1.80B (-100.0%)
|
| EPS |
3.96
est.
|
4.14
est.
|
2.69
est.
|
2.95
est.
|
3.98
est: 3.33 (+19.5%)
|
2.96
est: 4.40 (-32.8%)
|
1.80
est: 3.87 (-53.5%)
|
1.13
est: 1.87 (-39.6%)
|
1.65
est: 2.50 (-34.0%)
|
3.68
est: 2.15 (+71.2%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 19.0K | 0.33% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Te-Chung Tsai | GM, President, Chief Information Security Officer & Director | 3M | male |
| Shilong Gao | Head of Corporate Governance | — | — |
| Yu-Yin Cheng | Head of Finance, Accounting & Corporate Governance | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4175.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
